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Abstract 26	
 27	
A Trypanosoma brucei cell line is described that produces a visual readout of 28	
proteasome activity. The cell line contains an integrated transgene encoding an 29	
ubiquitin-green fluorescent protein (GFP) fusion polypeptide responsive to the 30	
addition of proteasome inhibitors. A modified version of T. brucei ubiquitin 31	
unable to be recognized by deubiquitinases (UbG76V) was fused to eGFP and 32	
constitutively expressed. The fusion protein is unstable but addition of the 33	
proteasome inhibitor lactacystin stabilizes it and leads to visually detectable 34	
GFP. This cell line can be widely used to monitor the efficiency of inhibitor 35	
treatment through detection of GFP accumulation in studies involving 36	
proteasome-mediated proteolysis, screening of proteasome inhibitors or other 37	
events related to the ubiquitin-proteasome pathway.  38	
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Main text 51	
 52	
The proteasome is a multi-catalytic ATP-dependent protease complex 53	
that plays a central role in the ubiquitin-mediated proteolysis, the major pathway 54	
for regulated degradation of multiple protein targets including cytosolic, nuclear 55	
and membrane polypeptides in all eukaryotic organisms1. The process of 56	
ubiquitination is mediated by three enzymes (E1, E2 and E3) that act in series 57	
to generate an isopeptide bond between the carboxyl group of the C-terminal 58	
glycine of ubiquitin and the amino group on the side chain of a lysine residue on 59	
the substrate. This can then result in degradation of the targeted protein by the 60	
proteasome whereas the ubiquitin is recycled following the action of 61	
deubiquitinases2. 62	
The ubiquitin-proteasome system has emerged as a therapeutic target 63	
for diverse pathologies such as cancer, neurodegenerative diseases, immune 64	
diseases and infections, including those caused by parasites3. Proteasome 65	
inhibitors are structurally diverse and can interact directly or allosterically with 66	
the proteasome active site(s), and can be reversible or irreversible4. 67	
Lactacystin, a β-lactone precursor from natural source, is an example of a 68	
potent and specific inhibitor of the proteasome proteolytic activity that binds 69	
irreversibly to the catalytic threonines found in the active sites of the 70	
proteasome β-subunits5,6. 71	
Trypanosoma brucei and T. cruzi are the causative agents of African 72	
Trypanosomiasis and Chagas disease, respectively, widespread tropical 73	
diseases that can be fatal if not treated. Lactacystin as well as other 74	
compounds, such as MG132, have been shown to inhibit proteasome activity in 75	
both T. brucei and T. cruzi, and studies using these compounds have helped to 76	
clarify the role of proteasomes in cell proliferation and differentiation in these 77	
pathogens7–9. Recently, studies have tested inhibitors of the kinetoplastid 78	
proteasome, including the molecule GNF6702, which showed selective effect in 79	
vivo, corroborating the idea that the proteasome is a potential target for 80	
treatment of infections caused by parasites10,11. 81	
Inhibitory concentrations of lactacystin and MG132 have been 82	
determined in Trypanosoma species8,12, however the time taken for them to 83	
cause primary effects has not been investigated in most studies in 84	
trypanosomatids; long incubations, usually over 10 hours, are used based on 85	
protocols developed for mammalian cells. These long incubations can make it 86	
difficult to distinguish primary and secondary effects of proteasome inhibition. 87	
To circumvent the problems above and to monitor the T. brucei response to 88	
lactacystin, we have produced a T. brucei reporter cell line based on the fusion 89	
of ubiquitin to a reporter fluorescent protein, an approach first developed in 90	
HeLa cells13. The T. brucei ubiquitin gene (Tb927.11.9920) encodes a 91	
polyubiquitin with nine tandem ubiquitin repeats. DNA fragments encoding 92	
single ubiquitin polypeptides (76 amino acids) were amplified using PCR, one 93	
containing an open reading frame (ORF) encoding wild type ubiquitin and a 94	
second designed to produce a mutation in the C-terminal amino acid of ubiquitin 95	
sequence, changing it from a glycine to a valine (G76V). Both PCR reactions 96	
also added 39 nucleotides encoding a 13 amino acid extension to the C-97	
terminus of the wild type or G76V ubiquitin. The purpose of this extension was 98	
to meet the requirements for ubiquitin recognition and cleavage by 99	
deubiquitinases (Figure 1A). Each PCR product was cloned between the EcoRI 100	
and HindIII sites of a modified version of p360514, which contains an eGFP ORF 101	
in a construct designed to insert into the tubulin locus by homologous 102	
recombination (Figure 1B). The result was two plasmids containing a transgene 103	
encoding a chimeric protein, either Ub-GFP (plasmid p4596) or Ub(G76V)-GFP 104	
(plasmid p4595). The mutation in Ub(G76V)-GFP means it is not cleaved by 105	
deubiquitinases and instead is degraded by the proteasome. Ub-GFP 106	
represented a control in which the polypeptide is cleaved by a deubiquitinase 107	
releasing stable GFP. The final constructs, p4595 and p4596, were cut with the 108	
restriction enzyme PacI and transfected into a procyclic form Trypanosoma 109	
brucei Lister427 pSMOx cell line15. Selection with 15 µg/ml geneticin (G418) in 110	
SDM-79 culture medium was used to select the respective cell lines, Lister427 111	
pSMOx p4595 and Lister427 pSMOx p4596. 112	
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Figure 1. Establishing the reporter cell lines. A) Sequence of the ubiquitin-green fluorescent proteins encoded by the transgenes. 128	
Ubiquitin is shown in blue with glycine 76, mutated to valine in the G76V variant, indicated in red; the linker is coloured in grey and the 129	
green fluorescent protein coding sequence in green. B) Representation of the insertion of the transgene construct into the tubulin locus 130	
by targeted homologous recombination. The construct resulted in the expression of a transgene mRNA with an alpha tubulin 5’UTR, 131	
transgene ORF and actin 3’UTR. Transcription was a result of read through by RNA polymerase II.  132	
Initially, the cell lines were incubated with 5 µM lactacystin in culture 133	
medium during log phase growth and GFP levels were detected by 134	
fluorescence microscopy and western blotting. The cell line containing the 135	
Ub(G76V)-GFP transgene had little GFP fluorescence before lactacystin 136	
addition consistent with being targeted for proteasomal degradation. After 137	
lactacystin addition, GFP fluorescence became apparent (Figure 2A) and a 138	
GFP fusion polypeptide with a molecular weight of ~35 kDa was detected by 139	
western blotting, consistent with the Ub(G76V)-GFP fusion protein (Figure 2B). 140	
In contrast, the cell line containing the Ub-GFP transgene constitutively 141	
expressed GFP, detected by fluorescence microscopy and as a 25 kDa 142	
polypeptide by western blot (Figure 2A and B). Expression of Ub(G76V)-GFP 143	
could also be detected after incubation with 10 µM MG132 (Figure 2C). Analysis 144	
by flow cytometry over a time course showed that the action of lactacystin and 145	
MG132 in accumulating Ub(G76V)-GFP occurred in the first hours of incubation 146	
(up to 8h) (Figure 2D), with GFP expression being detectable as early as 2 147	
hours of treatment.  148	
The readily detection of accumulated GFP in cells expressing Ub(G76V)-149	
GFP by either fluorescence microscopy or flow cytometry after treatment with 150	
lactacystin and MG132 indicates that the cell line is an excellent indicator for 151	
proteasome inhibition. It is a convenient tool for further studies involving the 152	
ubiquitin-proteasome pathway and screening of new proteasomal inhibitors. 153	
The plasmids are available from the authors upon request. 154	
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Figure 2. Detection of GFP expression after proteasome inhibition. A) 161	
Fluorescence microscopy detection of GFP expression before and after 162	
incubation with 5 µM lactacystin (+lact) for 6 hours. White scale bar = 5 µm. B) 163	
GFP expression in different cell lines detected by western blotting using anti-164	
GFP before and after incubation for 8 hours with 5 µM lactacystin as indicated. 165	
C) UbG76V-GFP is also expressed after incubation with 10 µM MG132 for 8 166	
hours. Cell lysates equivalent to 2x106 cells were loaded in each lane and 167	
detection of the chaperone BiP was used as loading control. D) Flow cytometry 168	
analysis of GFP expression by the reporter cell line Lister 427 pSMOx p4595 169	
during incubation with 5 µM lactacystin and 10 µM MG132 for 0, 2, 4, 6 and 8 170	
hours. For the flow cytometry experiments, the cell line Lister 427 pSMOx was 171	
used as negative control.  172	
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